Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports USA - English USA - English
The Floridant/10261535

MIRAMAR, Fla., Feb. 20, 2024 ~ Kimera® Labs Inc, a privately held clinical stage biotechnology company, has made a groundbreaking achievement in the field of targeted brain delivery. The company has successfully published an article in the prestigious Nature Scientific Reports journal, titled "Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain". This marks the first-ever publication of exosomes and a novel neural delivery breakthrough method in the Nature family of scientific journals.

The study was conducted by a world-class team of scientists from City of Hope, Regenesis Project, and Kimera® Labs. They collaborated to demonstrate that MSC derived exosomes manufactured by Kimera® can pass through the blood brain barrier (BBB) by employing a focused wave of ultrasound in a rat model. The team conducted a series of in vivo animal studies at City of Hope and concluded that a statistically significant amount of Kimera®'s exosomes penetrated the BBB when focused ultrasound was applied to a targeted region of the rat brain.

More on The Floridant
This achievement is considered a material advancement in the challenging field of targeted brain delivery by the scientific community. Duncan Ross PhD, cofounder and CEO of Kimera® Labs and co-author of the article, expressed his pleasure at this accomplishment. He stated, "We at Kimera® are pleased that our anti-inflammatory and regenerative exosomes have been recognized as instrumental in this neural breakthrough. This work would not have been possible without the collaboration and funding between Kimera labs® and our world-class team. We sincerely thank all 18 scientists involved for their strong collaborative effort."

The study presents exciting opportunities for neurology both scientifically and clinically. Dr. Sheldon Jordan, Professor of Neurology at UCLA and lead of the Regenesis Project, commented on its significance saying, "This study demonstrates a non-invasive and accessible means of targeted delivery across the blood brain barrier." He further added that this ability to selectively deliver exosomes to brain sites non-invasively with accessible technology should inspire the development of protocols for neuromodulation with cargoes including small molecules and epigenome modifying factors.

More on The Floridant
The article, which was published on October 18, 2023, can be accessed at This breakthrough comes after Kimera® Labs received its first Phase I/IIa IND approval to conduct human clinical trials for post-Covid patients on May 16, 2023. The company is now focused on advancing further neural scientific and clinical developments with its exosomes employing focused ultrasound.

Kimera® Labs' logo can be viewed at With this groundbreaking achievement, the company has solidified its position as a leader in the field of targeted brain delivery and is committed to continuing its research and development efforts towards improving neurological conditions.
Filed Under: Business

Show All News | Report Violation


Latest on The Floridant